GB201016912D0 - Novel combination - Google Patents

Novel combination

Info

Publication number
GB201016912D0
GB201016912D0 GBGB1016912.6A GB201016912A GB201016912D0 GB 201016912 D0 GB201016912 D0 GB 201016912D0 GB 201016912 A GB201016912 A GB 201016912A GB 201016912 D0 GB201016912 D0 GB 201016912D0
Authority
GB
United Kingdom
Prior art keywords
novel combination
novel
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1016912.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB1016912.6A priority Critical patent/GB201016912D0/en
Publication of GB201016912D0 publication Critical patent/GB201016912D0/en
Priority to KR1020137008725A priority patent/KR20130126595A/en
Priority to EP11781829.4A priority patent/EP2624838A1/en
Priority to JP2013532266A priority patent/JP2013538867A/en
Priority to AU2011311310A priority patent/AU2011311310A1/en
Priority to MX2013003816A priority patent/MX2013003816A/en
Priority to IN567MUN2013 priority patent/IN2013MN00567A/en
Priority to CN2011800589330A priority patent/CN103249418A/en
Priority to BR112013008362A priority patent/BR112013008362A2/en
Priority to PCT/GB2011/051898 priority patent/WO2012046050A1/en
Priority to RU2013115103/15A priority patent/RU2013115103A/en
Priority to SG2013019666A priority patent/SG188575A1/en
Priority to CA2813684A priority patent/CA2813684A1/en
Priority to IL225312A priority patent/IL225312A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
GBGB1016912.6A 2010-10-07 2010-10-07 Novel combination Ceased GB201016912D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination
CA2813684A CA2813684A1 (en) 2010-10-07 2011-10-05 Novel combinations
IN567MUN2013 IN2013MN00567A (en) 2010-10-07 2011-10-05
BR112013008362A BR112013008362A2 (en) 2010-10-07 2011-10-05 combinations
JP2013532266A JP2013538867A (en) 2010-10-07 2011-10-05 Novel combination
AU2011311310A AU2011311310A1 (en) 2010-10-07 2011-10-05 Novel combinations
MX2013003816A MX2013003816A (en) 2010-10-07 2011-10-05 Novel combinations.
KR1020137008725A KR20130126595A (en) 2010-10-07 2011-10-05 Novel combinations
CN2011800589330A CN103249418A (en) 2010-10-07 2011-10-05 Novel combinations
EP11781829.4A EP2624838A1 (en) 2010-10-07 2011-10-05 Novel combinations
PCT/GB2011/051898 WO2012046050A1 (en) 2010-10-07 2011-10-05 Novel combinations
RU2013115103/15A RU2013115103A (en) 2010-10-07 2011-10-05 NEW COMBINATIONS
SG2013019666A SG188575A1 (en) 2010-10-07 2011-10-05 Novel combinations
IL225312A IL225312A0 (en) 2010-10-07 2013-03-18 Novel combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination

Publications (1)

Publication Number Publication Date
GB201016912D0 true GB201016912D0 (en) 2010-11-24

Family

ID=43304217

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1016912.6A Ceased GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination

Country Status (14)

Country Link
EP (1) EP2624838A1 (en)
JP (1) JP2013538867A (en)
KR (1) KR20130126595A (en)
CN (1) CN103249418A (en)
AU (1) AU2011311310A1 (en)
BR (1) BR112013008362A2 (en)
CA (1) CA2813684A1 (en)
GB (1) GB201016912D0 (en)
IL (1) IL225312A0 (en)
IN (1) IN2013MN00567A (en)
MX (1) MX2013003816A (en)
RU (1) RU2013115103A (en)
SG (1) SG188575A1 (en)
WO (1) WO2012046050A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027922A (en) * 2013-09-04 2015-03-13 주식회사 대웅제약 Novel antifungal pyridinylhydrazide derivatives
KR101657678B1 (en) * 2013-11-05 2016-09-20 주식회사 대웅제약 Novel compound, method for preparation thereof, and antifungal composition comprising the same
MA43250B1 (en) * 2015-11-16 2022-12-30 Esteve Pharmaceuticals Sa Oxadiazaspiro compounds for the treatment of drug abuse and dependence
CN109195975B (en) * 2016-09-30 2022-01-04 四川海思科制药有限公司 Diazaspiro [5.5] undecane derivative and application thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2296923T3 (en) 2001-03-22 2008-05-01 Glaxo Group Limited FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
KR20090057477A (en) 2001-09-14 2009-06-05 글락소 그룹 리미티드 Phenethanolamine derivatives for treatment of respiratory diseases
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AR040661A1 (en) 2002-07-26 2005-04-13 Theravance Inc CRYSTAL DICHLORHYDRATE OF N- {2 - [- ((R) -2-HYDROXI-2-PHENYLETHYLAMINE) PHENYL] ETIL} - (R) -2 HYDROXY-2- (3-FORMAMIDE-4-HYDROXYPHENYL) ETHYLAMINE, RECEIVER AGONIST BETA 2 ADRENERGIC
ATE392206T1 (en) 2002-10-11 2008-05-15 Pfizer INDOLE DERIVATIVES AS BETA-2 AGONISTS
DE60320007T2 (en) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamine derivatives for the treatment of respiratory diseases
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
ATE435862T1 (en) 2003-05-28 2009-07-15 Theravance Inc AZABICYCLOALKAN COMPOUNDS AS MUSCARINE RECEPTOR ANTAGONISTS
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (en) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
US7402673B2 (en) 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
US20060002967A1 (en) 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060114254A1 (en) 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006066907A1 (en) 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
GEP20115357B (en) 2006-03-20 2011-12-26 Pfizer Ltd Amine derivatives
ES2296516B1 (en) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP2010500318A (en) 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment of respiratory diseases
PE20081358A1 (en) 2006-08-22 2008-10-31 Boehringer Ingelheim Int PHARMACOLOGICAL COMBINATIONS FOR THE TREATMENT OF DISEASES OF THE AIRWAY
RS20090137A (en) 2006-10-04 2010-06-30 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
ES2302447B1 (en) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
SA08280783B1 (en) 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
WO2008106016A2 (en) 2007-02-27 2008-09-04 Metrosol, Inc. Prism spectrometer with moveable detector element and with collimated input light
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
CA2691215C (en) 2007-06-27 2016-03-29 Astrazeneca Ab Pyrazinone derivatives and their use in the treatment of lung diseases
CA2700181A1 (en) * 2007-10-04 2009-04-09 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
SI2242759T1 (en) 2008-02-06 2013-01-31 Astrazeneca Ab Compounds
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
US20110190309A1 (en) 2008-05-13 2011-08-04 Rhonan Ford PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802

Also Published As

Publication number Publication date
BR112013008362A2 (en) 2016-06-14
CA2813684A1 (en) 2012-04-12
IN2013MN00567A (en) 2015-10-09
IL225312A0 (en) 2013-06-27
KR20130126595A (en) 2013-11-20
MX2013003816A (en) 2013-05-01
CN103249418A (en) 2013-08-14
EP2624838A1 (en) 2013-08-14
WO2012046050A1 (en) 2012-04-12
SG188575A1 (en) 2013-04-30
RU2013115103A (en) 2014-11-20
JP2013538867A (en) 2013-10-17
AU2011311310A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
EP2547244A4 (en) Combination juicer-blender
EP2640189A4 (en) 3-deutero-pomalidomide
EP2534256A4 (en) Novel uses
EP2651505A4 (en) Electroporation-induced electrosensitization
EP2641891A4 (en) Pkc- activator
GB201013207D0 (en) Novel combination
EP2572199A4 (en) Combination
IL225312A0 (en) Novel combinations
EP2571358A4 (en) Combination
GB201000196D0 (en) Novel combination
EP2603078A4 (en) Combination
EP2575460A4 (en) Combination
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
GB201013214D0 (en) Novel combination
GB201013212D0 (en) Novel combination
GB201013209D0 (en) Novel combination
GB201013211D0 (en) Novel combination
GB201005318D0 (en) Novel combination
GB201002829D0 (en) Novel copmounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)